whatshot

RGBP   $0.0019  0.0 Market Open

Regen BioPharma Inc
show_chart Advanced Chart of RGBP
Last Events:

2023-03-29 Signal in MACD changed from bearish weakening to bearish. Oscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: signal line crossed the middle level.

2023-03-29 Signal in RSI changed from bullish to bearish recovery. RSI indicator is in the oversold territory and it heading south. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: exit from the overbought zone.

2023-03-29 Trend changed from down and flat to flat and down.

2023-03-29 Signal in MACD changed from bearish to bearish weakening. Oscillator MACD is in the negative territory it's higher than the signal line and grows. These factors mean that the falling period is over. Last signal: main and signal line crossing.

2023-03-29 Signal in RSI changed from bearish recovery to bullish. RSI indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: entrance to the overbought zone.

2023-03-29 Trend changed from flat and down to down and flat.

2023-03-28 Signal in MACD changed from bearish weakening to bearish. Oscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: signal line crossed the middle level.

2023-03-28 Signal in RSI changed from bullish to bearish recovery. RSI indicator is in the oversold territory and it heading south. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: exit from the overbought zone.

Current temperature: 0.00
ST: 0, Cor:

Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi - Sell Sell
macd - Sell Sell
stoch Sell Sell -
ma20 - - -
ma50 - - -
ma100 - - -
Candlestick PatternMarch 1, 2023 Three Stars -
ISIN US75886M1027
ceo Dr. David Raymond Koos DBA, Ph.D.
Website https://regenbiopharmainc.com
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is involved in the development of its products, and therapies, including HemaXellarate, a cellular therapeutic product of autologous stromal vascular fraction derived from adipose tissue; dCellVax, an autologous dendritic cell which is treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax which is treated with siRNA to inhibit NR2F6 and the cells re-infused to the patient; DiffronC, uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuroCAR comprising of CAR-T cells which is treated with an shRNA targeting the gene NR2F6. The company was incorporated in 2012 and is based in La Mesa, California.